John R Fischer

KKR looks to leverage growth of biopharma royalties with HCRx

'We’re seeing a lot of capital needs not only across the therapeutic side of life sciences but also this biopharma ecosystem of all of the companies that serve these biopharma businesses,' said KKR's Ali Satvat.

KKR, LDC, TPG eye travel tech; Great Hill expands reach in pediatric dental care

Also, we have dealmaking insights from Bailey & Company’s Q2 2025 Healthcare M&A Spotlight report.

Lee Equity to sell urology platform for $1.9bn to Cardinal Health; Bain, Arlington, Revelstoke invest in immunotherapy; H1 healthcare deals that mattered

In urology dealmaking, the landscape is highly fragmented and includes profitable ancillary services for diverse revenue streams.

PE targets immunotherapy: Five deals

Bain Capital, 65 Equity Partners, Arlington Capital Partners and Revelstoke Capital Partners are among the PE firms investing in the immunotherapy sector.

Advice for healthcare dealmakers on navigating Medicaid and reimbursement challenges

'Before you sign on the dotted line, make sure you understand where the checks are coming from, how they’re earned and what strings might be attached,' urges Polsinelli's Ryan Thurber.

Apollo, Blackstone, Carlyle, KKR celebrate expanded access to 401(k) investing; Brynwood, Butterfly and Gryphon target beverage deals

Reactions from Apollo, Blackstone, The Carlyle Group and Hamilton Lane on Trump's executive order allowing 401(k) investors to access private equity; a five-deal listicle looking at PE’s interest in the beverage industry; a look at KKR’s recap of a revenue cycle management company serving the US dental industry.

Bain Capital expects PCI to benefit from nearshoring dynamics in biopharma

'Pharma is looking for fewer, scaled providers at an enterprise level to reduce risk and provide a better-integrated service,' said Bain Capital’s Sam Weil.

Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz

Rounding up five deals in the home healthcare sector, which has caught the attention of Accel-KKR, Berkshire Partners, Carlyle, Vistria and other PE firms; a look at the launch of Bain Capital’s and Bristol Myers Squibb’s new autoimmune biopharma company; insights into the commercialization and market access to the services side of the pharma sector from a report by the investment bank Bourne Partners.

PE bets on home healthcare software: 5 deals

Accel-KKR, Berkshire Partners, Carlyle, Heritage Group and Vistria are among the PE firms investing in software for home healthcare.

Clearview, Grovecourt, Vistria bet on telehealth platforms; Northlane sells cost containment biz to Stone Point Capital

Private equity sees attractive demand and growth opportunities within the fragmented healthcare cost containment service market